13D Filing: DAFNA Capital Management and Stereotaxis Inc. (STXS)

Page 3 of 8 – SEC Filing


CUSIP: 85916J409 SCHEDULE 13D
  1

NAMES OF
REPORTING PERSON

Dr. Nathan Fischel

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP

(a)  ☐        (b)  ☐

  3

SEC USE ONLY

  4

SOURCE OF FUNDS

AF

  5

CHECK BOX IF DISCLOSURE OF LEGAL
PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  6

CITIZENSHIP OR PLACE OF
ORGANIZATION

Austria citizen (U.S. permanent resident)

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

  7

SOLE VOTING POWER

10,000 (3)

  8

SHARED VOTING POWER

13,680,554 (4)

  9

SOLE DISPOSITIVE POWER

10,000 (3)

10

SHARED DISPOSITIVE POWER

13,680,554 (4)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

13,690,554 (3)(4)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (11) EXCLUDES CERTAIN SHARES

13

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (11)

23.4%
(5)

14

TYPE OF REPORTING PERSON

IN, HC

(3) Consists of vested shares of restricted Common Stock held by Dr. Nathan Fischel. Excludes unvested shares of restricted Common Stock held by Dr. Nathan Fischel.
(4) Consists of shares of Common Stock held by DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P. Dr. Nathan Fischel is the Chief Executive Officer of DAFNA, which is the investment manager and general partner
of each of the Funds. Excludes shares of Common Stock issuable upon conversion of preferred stock as well as shares of Common Stock issuable upon exercise of warrants held by the Funds as a result of the Beneficial Ownership Limitation described
herein. See Item 5 of this Amendment No. 4 to the Schedule 13D for further details.
(5) See Item 5 of this Amendment No. 4 to the Schedule 13D.

Page 3 of 8

Follow Stereotaxis Inc. (NASDAQ:STXS)